Literature DB >> 17103254

Clinicopathological features and prognosis in resectable synchronous and metachronous colorectal liver metastasis.

Ming-Shian Tsai1, Yen-Hao Su, Ming-Chih Ho, Jin-Tung Liang, Tzu-Ping Chen, Hong-Shiee Lai, Po-Huang Lee.   

Abstract

INTRODUCTION: Hepatic resection may offer long-term survival for patients with colorectal metastases. However, controversies exist regarding the prognostic factors. Herein, the impact of synchronicity of liver metastasis on patient clinicopathological features and prognosis was evaluated.
METHODS: One hundred and fifty-five patients who underwent hepatectomy for colon cancer metastasis, from 1995 to 2004, were enrolled in this study. Patients were divided into two groups: synchronous and metachronous colorectal liver metastasis. Patient demographics, the nature of the primary and metastatic tumors, surgery-related complications, and long-term outcome were analyzed.
RESULTS: Patients included in the synchronous group tended to be younger than those in the metachronous group. Compared to the metachronous group, patients in the synchronous group showed more metastases (P = 0.008) and bilobarly distributed metastases (P = 0.016). Bile leakage was the most common surgical complication. The estimated 5-year disease-free and overall survival rates were 16.8 and 41.1%, respectively. Univariate analysis indicated that synchronous metastases, advanced stage of the primary tumor, bilobar distribution of the metastases, more than three metastases, and colonic versus rectal location of the primary tumor were prognostic factors of shorter disease-free survival, but not overall survival. Multivariate analysis revealed that synchronous metastases and the advanced stage of the primary tumor were indicators for a worse disease-free survival.
CONCLUSION: The synchronous presence of primary colon cancer and liver metastasis may indicate a more disseminated disease status and is associated with a shorter disease-free survival than metachronous metastasis. These patients may need more careful monitoring and aggressive chemotherapy following curative resection.

Entities:  

Mesh:

Year:  2006        PMID: 17103254     DOI: 10.1245/s10434-006-9215-5

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  63 in total

1.  Safety analysis of the oncological outcome after vein-preserving surgery for colorectal liver metastases detached from the main hepatic veins.

Authors:  Federico Tomassini; Italo Bonadio; Peter Smeets; Karen De Paepe; Giammauro Berardi; Liesbeth Ferdinande; Stéphanie Laurent; Louis J Libbrecht; Karen Geboes; Roberto I Troisi
Journal:  Langenbecks Arch Surg       Date:  2015-08-12       Impact factor: 3.445

2.  Treatment Outcome of Resection of Disseminated Peritoneal Metastases from Colorectal Cancer.

Authors:  Gaku Ohira; Hideaki Miyauchi; Koichi Hayano; Michihiro Maruyama; Shunsuke Imanishi; Toru Tochigi; Tetsuro Maruyama; Toshiharu Hanaoka; Koichiro Okada; Hisahiro Matsubara
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

3.  Long non-coding RNA slincRAD functions in methylation regulation during the early stage of mouse adipogenesis.

Authors:  Fan Yi; Pei Zhang; Yao Wang; Yin Xu; Zhengxi Zhang; Weizhi Ma; Bo Xu; Qing Xia; Quan Du
Journal:  RNA Biol       Date:  2019-06-19       Impact factor: 4.652

Review 4.  Musculoskeletal Metastasis from Primary Rectal Cancer: Series of Two Cases of a Very Rare Occurrence with a Short Literature Review.

Authors:  Sankalp Singh; Niharika Bisht; Richa Joshi; Prabha Shankar Mishra; Deepak Mulajker; Samir Gupta
Journal:  J Gastrointest Cancer       Date:  2019-12

5.  TISSUE REGENERATION. Inhibition of the prostaglandin-degrading enzyme 15-PGDH potentiates tissue regeneration.

Authors:  Yongyou Zhang; Amar Desai; Sung Yeun Yang; Ki Beom Bae; Monika I Antczak; Stephen P Fink; Shruti Tiwari; Joseph E Willis; Noelle S Williams; Dawn M Dawson; David Wald; Wei-Dong Chen; Zhenghe Wang; Lakshmi Kasturi; Gretchen A Larusch; Lucy He; Fabio Cominelli; Luca Di Martino; Zora Djuric; Ginger L Milne; Mark Chance; Juan Sanabria; Chris Dealwis; Debra Mikkola; Jacinth Naidoo; Shuguang Wei; Hsin-Hsiung Tai; Stanton L Gerson; Joseph M Ready; Bruce Posner; James K V Willson; Sanford D Markowitz
Journal:  Science       Date:  2015-06-12       Impact factor: 47.728

6.  A specific KRAS codon 13 mutation is an independent predictor for colorectal cancer metachronous distant metastases.

Authors:  Qingyang Feng; Li Liang; Li Ren; Jingwen Chen; Ye Wei; Wenju Chang; Dexiang Zhu; Qi Lin; Peng Zheng; Jianmin Xu
Journal:  Am J Cancer Res       Date:  2015-01-15       Impact factor: 6.166

7.  Accomplishments in 2008 in the management of curable metastatic colorectal cancer.

Authors:  René Adam; Emir Hoti; Gunnar Folprecht; Al B Benson
Journal:  Gastrointest Cancer Res       Date:  2009-09

8.  Mapping of genetic abnormalities of primary tumours from metastatic CRC by high-resolution SNP arrays.

Authors:  José María Sayagués; Celia Fontanillo; María del Mar Abad; María González-González; María Eugenia Sarasquete; Maria del Carmen Chillon; Eva Garcia; Oscar Bengoechea; Emilio Fonseca; Marcos Gonzalez-Diaz; Javier De las Rivas; Luís Muñoz-Bellvis; Alberto Orfao
Journal:  PLoS One       Date:  2010-10-29       Impact factor: 3.240

9.  Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases.

Authors:  L J M Mekenkamp; M Koopman; S Teerenstra; J H J M van Krieken; L Mol; I D Nagtegaal; C J A Punt
Journal:  Br J Cancer       Date:  2010-06-15       Impact factor: 7.640

10.  Defining patient outcomes in stage IV colorectal cancer: a prospective study with baseline stratification according to disease resectability status.

Authors:  D J Watkins; I Chau; D Cunningham; S S Mudan; N Karanjia; G Brown; S Ashley; A R Norman; A Gillbanks
Journal:  Br J Cancer       Date:  2010-01-19       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.